Abstract
IntroductionSodium-glucose cotransporter 2 (SGLT2) inhibitors are believed to lower glucose levels and inhibit cardiovascular events related to type 2 diabetes (T2D). To maximize their benefits, the risk of resultant hypoglycemia...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have